27
Oct 2026
Researchers develop versatile genetic tool to investigate cell interactions
Our bodies are composed of many different types of cells that work together to build and maintain normal physiological functions.
Stay Informed!
27
Oct 2026
Hēlo system offers minimally invasive solution for chronic venous thromboembolism
Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated.
26
Oct 2026
New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1 trial published in The Journal of Nuclear Medicine's Late-Breaking Fast Track.
26
Oct 2026
Dismissive consultations leave some autoimmune patients distressed and suicidal
Patients have been left feeling suicidal after feeling like their doctor was saying their symptoms were 'all in their head' – according to research from the University of East Anglia and the University of Cambridge.
26
Oct 2026
Genetic findings illuminate dental abnormalities and the evolutionary loss of teeth
Rare variants in a gene involved in early development have been linked to a range of dental differences in people, including missing teeth, unusual tooth shapes, and teeth present at birth.
26
Oct 2026
Millions get GLP-1 drugs through channels insurance records may miss
Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% between March 2024 and October 2025, largely driven by weight-loss indications. They also estimated that approximately one-third of users obtained treatment through nontraditional channels that standard insurance claims may fail to capture.
26
Oct 2026
Immunotherapy combination sets a new standard of care for extensive-stage small cell lung cancer
In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival, and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study, which was presented by Jacob Sands, MD, Associate Chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24.
26
Oct 2026
AI drug recommendations show bias toward costly branded products
Large language models (LLMs), such as ChatGPT and Claude, are increasingly being used to provide health information to the public.
26
Oct 2026
Semaglutide changes gut bacteria in rats beyond what eating less explains
Researchers compared semaglutide-treated male and female rats with pair-fed animals receiving the same amount and type of food to distinguish drug-associated microbiome changes from those linked to reduced eating. Semaglutide altered bacterial richness and community composition, with some changes absent from the pair-fed groups and uncertain consequences for health.
26
Oct 2026
Beer and liquor show more oral bacteria links than wine in a large US study
Researchers analyzed beverage intake and oral microbiome data from 5,598 adults across three US cohorts and found that alcohol consumption showed the strongest associations with oral bacterial diversity and composition among the beverages examined. Higher alcohol intake was associated with greater bacterial richness and differences in genera linked to oral health, but the cross-sectional preprint could not establish whether alcohol caused these differences or influenced disease risk.
